50% off Premium Yearly

NYSE:NCLH
This summary was created by AI, based on 1 opinions in the last 12 months.
Norwegian Cruise Line Holdings (NCLH) is under scrutiny as it prepares to report its results on Monday, with activist investor Elliot Management pushing for substantial changes to enhance its competitive standing relative to peers like Royal Caribbean and Viking. Elliot, known for its strong track record in influencing corporate strategies, advocates for a timely sale of NCLH to Disney, arguing that acquiring existing cruise ships would be a more efficient solution for Disney's fleet expansion than engaging in long-term shipbuilding projects which can take up to five years. The current dynamics within the cruise industry and the performance of NCLH compared to its competitors indicate a potential for strategic realignment that could benefit all stakeholders involved. The pressure from Elliot Management could spur significant developments for NCLH, and a focus on agility over traditional growth methods may redefine its operational framework going forward.
Carnival vs. Norwegian cruiselines He's not buying any cruiselines. Carnival just raised $6 billion, so they have the capital to ride this out, so it's better. But look at another sector or industry.
The airlines and luxury goods stocks are in the same basket as the cruiselines during the coronavirus outbreak. These stocks will be fine eventually. The emerging middle class wants to travel. Travel is strong. The chart hasn't moved in three years, so you got to time your entries and exits to capitalize.
The world’s third-largest cruise company by berth, in terms of number of total beds. Operates about 25 ships across 3 different brands. They plan to introduce 7 more ships through 2025, meaning they are going to increase capacity much faster than Royal or Carnival. Has a lot of runway when it comes to China, Europe, etc. because they are not as well exposed there. They have freestyle cruising which allows the older demographics to bring families on board. (Analysts’ price target is $65.)